JAK Inhibitors for ET and PV: What have we learned so far?

JAK Inhibitors for ET and PV: What have we learned so far?

HMP CME

4 years
266 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
In this presentation from the 2016 "European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes", Dr. Gunnar Birgegård discusses what we have learned so far regarding the use of JAK inhibitors in the treatment of essential thrombocythemia (ET) and polycythemia vera (PV). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.
Up Next Autoplay